In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Crawford “review”

This article was originally published in The Tan Sheet

Executive Summary

The HHS Office of the Inspector General is "reviewing the circumstances" surrounding the resignation of FDA Commissioner Lester Crawford in response to requests from members of Congress, IG Daniel Levinson confirmed in a recent letter to Rep. Maurice Hinchey (D-N.Y.) and colleagues. "Depending upon the results of the review, we will determine the next appropriate action," Levinson said. According to OIG staff, the review currently is not a formal investigation. Lawmakers called for the investigation in September (1"The Tan Sheet," Oct. 3, 2005, p. 4)...

You may also be interested in...

Hinchey presses FDA

Rep. Maurice Hinchey (D-N.Y.) will use an upcoming hearing on FDA's budget request to pose questions about conflicts of interest to Acting Commissioner Andrew von Eschenbach, Hinchey's office says. Von Eschenbach is scheduled to discuss FDA's budget request for fiscal 2007 at a Feb. 16 hearing held by the Appropriations Subcommittee on Agriculture, Rural Development, FDA & Related Agencies. Hinchey says his questions will center on "von Eschenbach's own conflict as NCI Director," FDA's recently restated policy of preemption and the agency's "cozy relationship" with the drug industry. The congressman has campaigned to prevent scientists and doctors with conflicts of interest from participating on FDA committees. In September, he requested that the HHS Office of the Inspector General review the resignation of former FDA Commissioner Lester Crawford (1"The Tan Sheet" Oct. 31, 2005, In Brief)...

FDA Works To Stay Focused As Its Heads Spin; Deputies In Spotlight

A key challenge for FDA following the resignation of Commissioner Lester Crawford will be overcoming the impression that being without a permanent leader yet again will result in a period of stasis at the agency

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts